Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus standard chemotherapy as first-line therapy for unresectable advanced gastric and gastroesophageal junction adenocarcinoma
ChiCTR2300077373Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of sintilimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Objective response rate and Progression-free survival. Started Nov 2022; status: recruiting.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300077373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077373.